Ocuphire Pharma Investor Update

RM Percent of Subjects (%) 18 100% 80% 60% 40% 20% 0% Primary Endpoint Achieved in Two FDA Registration Phase 3 Trials Rapid, Consistent and Sustained Reversal of Pupil Dilation with Nyxol Percent of Subjects Returning to ≤ 0.2 mm of Baseline PD Study Eye (mITT) 4%4% 0.5 MIRA-3 Phase 3 Trial p<0.000 42% 2% 1 p<0.0001 58% 6% 1.5 p<0.0001 7% 66% 2 p<0.0001 79% 14% 3 p<0.0001 86% 17% 4 p<0.0001 p<0.0001 91% 89% 36% 6 72% 24 Placebo (n=124) Nyxol (n=244) Time Post-Treatment with Nyxol/Placebo (Hours) 100% Percent of Subjects (%) 80% 60% 40% 20% 0% 3% 1% 0.5 Placebo n=91 Percent of Subjects Returning to ≤ 0.2 mm of Baseline PD Study Eye (mITT) p<0.0001 90% p<0.0001 28% 2% 1 MIRA-2 Phase 3 Trial p<0.0001 49% 7% ■Nyxol n=94 1.5 p<0.0001 59% 11% 2 p<0.0001 80% 18% 3 p<0.0001 82% 30% 4 45% Source: (Left panel) MIRA-3 Table 14.2.1.1 (mITT); (Right panel) MIRA-2 Table 14.2.1.1 (mITT). Data include all three mydriatics (Phenylephrine, Tropicamide, Paremyd). 6 p<0.0001 92% 66% 24 Time Post-Treatment with Nyxol/Placebo (Hours) Ocuphire PHARMA

View entire presentation